国家神经系统疾病临床医学研究中心数据管理与共享系统

The prognosis of primary GSM is still poor despite aggressive surgical resection and adjuvant multi-modality therapy is given. GSM in China may be managed similarly to GBM, with maximal safe surgical resection followed by chemo-radiotherapy. Adjuvant chemotherapy based on TMZ, currently one of the main treatment options for GBM, seems to have no definite survival benefit for GSM, which may be ascribed to rare MGMT methylation and IDH1 mutation in GSM. Our study adds further evidence to support GSM as a unique clinical entity with a likely worse prognosis than GBM. Further rigorous research into the clinical, genomic and molecular characteristics of GSM is required to better understand this malignant brain tumor.